Fundacio Puigvert

Fundacio Puigvert in Barcelona is active in a broad nephrology portfolio focused on improving care for people with chronic and inherited kidney disorders. The research includes studies on IgA nephropathy, focal segmental glomerulosclerosis, primary membranous nephropathy, Alport syndrome, and autosomal dominant polycystic kidney disease, with trials designed to test new therapies, slow disease progression, and preserve kidney function.

• Studies in IgA nephropathy and related proteinuric kidney diseases
• Research on inherited disorders such as Alport syndrome and ADPKD
• Evaluation of treatments aimed at reducing proteinuria and protecting renal function

The site’s kidney-focused trials reflect a strong interest in both rare disease management and more common progressive renal conditions, supporting advances in treatment effectiveness and long-term safety.

Another major research area at Fundacio Puigvert is kidney transplantation, where trials examine ways to improve graft outcomes, prevent rejection, and reduce infection risk. The studies address delayed graft function, individualized immunosuppression, and treatment strategies for transplant recipients with infections or other complications.

• Approaches to reduce delayed graft function after transplant
• Trials on personalized immunosuppressive therapy and rejection prevention
• Studies evaluating safer and more effective care for transplant-related infections

This work is aimed at improving both short-term recovery and long-term graft survival for people receiving kidney transplants.

The site also conducts extensive research in urologic oncology, especially non-muscle invasive bladder cancer, muscle-invasive bladder cancer, and upper tract urothelial carcinoma. These studies are testing new treatment options and combinations to improve tumor control, reduce recurrence, and expand choices for patients who do not respond well to standard care.

• Trials in high-risk and BCG-unresponsive bladder cancer
• Research on upper tract urothelial carcinoma and related urinary tract cancers
• Evaluation of novel therapies to improve disease-free and event-free survival

At Fundacio Puigvert, this oncology research is centered on finding more effective bladder-sparing and kidney-preserving treatment strategies.

Several trials at the site examine cardiovascular diseases and related risk factors, particularly in patients with kidney disease or hypertension. Research in this area includes efforts to better control high blood pressure, lower cardiovascular risk, and understand how treatment may reduce major heart and vascular events.

• Studies in hypertension and high cardiovascular risk
• Research linking kidney disease management with cardiovascular protection
• Trials assessing whether new treatments can reduce serious heart and vascular outcomes

This line of research reflects the close connection between kidney health and cardiovascular health in everyday clinical care.

The clinical trial portfolio at this hospital also includes studies in reproductive and urinary physiological phenomena and related male and female urogenital conditions. These trials address issues such as male factor infertility and other urinary tract disorders, with the goal of improving care options and patient outcomes.

• Research involving male urogenital disease and fertility-related concerns
• Studies addressing urinary tract function and related health problems
• Trials aimed at evaluating new supportive or symptom-focused treatments

While smaller in volume than the kidney and oncology programs, these studies broaden the site’s scope across important areas of urogenital medicine.